Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Brain Health as the Underlying Goal of Therapy in Multiple Sclerosis

Treatment in MS

Treatment Goal: Brain Health

Brain Health Goals

Domains of Brain Health

Minimizing MS Damage to the Brain

Promote Wellness and Control Environmental Factors

Promote Wellness and Control Environmental Factors (cont)

Minimizing Comorbidities in MS

Concluding Remarks

Strategies for Maintaining Brain Health in RRMS

Brain Health and Cognitive Reserve

Brain Size and Cognition

Comorbidities in MS

Common Comorbidities

Impact of Comorbidities

Comorbidities and Treatment Considerations

Strategies to Optimize Brain Health

Defining the Role of Brain Health in Progressive MS

MS Treatment Goals

Markers of Brain Health

Markers of Brain Health (cont)

Neurologic Reserve

Brain Reserve and Capacity to Accommodate Injury Evidence From AD

Cognitive Reserve

Ocrelizumab Brain Volume Reduction in RRMS

Alemtuzumab Brain Volume Reduction in RRMS

Ocrelizumab in PPMS

Conclusions

Shared Decision Making in Multiple Sclerosis

Approach to the Treatment of MS

DMTs for the Treatment of MS

Treatment Decision Making

Adherence in MS

Setting Realistic Expectations

Decision-Making Preferences in MS

Finding the Value Proposition of Modern MS Therapeutics

DMT Treatments and Cost

Economic Perspective: Value of Goods

Fingolimod vs IFNβ-1a in RRMS

Early initiation of Fingolimod Treatment in RRMS

Natalizumab vs Fingolimod in RRMS

Timing of High-Efficacy Therapies

Ocrelizumab in RRMS and PPMS

Alemtuzumab in RRMS

Cladribine in RRMS

Concluding Remarks

Abbreviations

Abbreviations (cont)